Mark X. Sliwkowski

Mark X. Sliwkowski's AcademicInfluence.com Rankings

Mark X. Sliwkowski

Biology

#11764

World Rank

#15187

Historical Rank

Molecular Biology

#1847

World Rank

#1876

Historical Rank

Neuroscience

#1936

World Rank

#1992

Historical Rank

Biochemistry

#1959

World Rank

#2100

Historical Rank

biology Degrees

Download Badge

Biology

Mark X. Sliwkowski's Degrees

PhD Biochemistry University of California, Berkeley
Bachelors Biochemistry University of California, Davis

Why Is Mark X. Sliwkowski Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mark X. Sliwkowski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Untangling the ErbB signalling network (2001) (6547)
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008) (1387)
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* (2002) (1051)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (2004) (1043)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (2008) (1034)
Identification of Heregulin, a Specific Activator of p185erbB2 (1992) (982)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. (2003) (930)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (2002) (884)
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (2009) (793)
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012) (789)
Treatment of HER2-positive breast cancer: current status and future perspectives (2012) (767)
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). (1999) (720)
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers (1999) (710)
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. (1994) (667)
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. (1995) (664)
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (2008) (623)
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. (2010) (537)
Antibody Therapeutics in Cancer (2013) (483)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. (2004) (469)
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. (1993) (461)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer (2011) (452)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer (2011) (399)
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. (2005) (398)
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. (2006) (388)
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. (2000) (387)
Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. (1997) (384)
Binding specificities and affinities of egf domains for ErbB receptors (1999) (376)
The erbB3 gene product is a receptor for heregulin. (1994) (353)
Oncogenic ERBB3 mutations in human cancers. (2013) (328)
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. (2011) (306)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab (2006) (291)
Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. (1995) (280)
The influence of heregulins on human Schwann cell proliferation (1995) (255)
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2010) (242)
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. (2010) (214)
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. (2001) (198)
Identification of Gas6 as a growth factor for human Schwann cells (1996) (188)
Overexpression of HER2/neu in solid tumours: an immunohistochemical survey (2001) (174)
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. (2013) (163)
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy (2013) (159)
Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. (1996) (155)
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells (1999) (152)
CD20: a gene in search of a function. (2000) (150)
Regulation of the acetylcholine receptor ϵ subunit gene by recombinant ARIA: An in vitro model for transynaptic gene regulation (1995) (125)
Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. (1994) (125)
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) (2014) (124)
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab (2009) (124)
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects (2004) (107)
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice (2010) (106)
Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model (2012) (103)
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (102)
γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175 (1997) (99)
A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. (2001) (97)
Preclinical studies with Erlotinib (Tarceva). (2003) (97)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells (2018) (92)
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. (2011) (92)
Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. (1998) (89)
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. (2014) (80)
Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association* (2002) (76)
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (2010) (71)
Association of Csk-homologous Kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in Breast Cancer Cells* (1997) (70)
Perspectives on Anti-HER Monoclonal Antibodies (2002) (69)
Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro. (2000) (68)
Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms (2009) (66)
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. (2017) (65)
Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4 (1998) (64)
High-resolution solution structure of the EGF-like domain of heregulin-alpha. (1996) (59)
Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. (1996) (59)
Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC (2014) (57)
Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis* (1998) (56)
High cell-surface density of HER2 deforms cell membranes (2016) (55)
Design, Construction, and In Vitro Analyses of Multivalent Antibodies (2003) (54)
Heregulin enhances regenerative proliferation in postnatal rat utricular sensory epithelium after ototoxic damage (1999) (53)
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. (2011) (52)
Incorporation and distribution of selenium into thiolase from Clostridium kluyveri. (1985) (47)
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. (2014) (47)
A potential role for activated HER-2 in prostate cancer. (2000) (46)
Ready to partner (2003) (45)
Insulin Regulates Heregulin Binding and ErbB3 Expression in Rat Hepatocytes* (1996) (43)
Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display* (1998) (42)
Catalytic effect of sulfhydryl oxidase on the formation of three-dimensional structure in chymotrypsinogen A. (1978) (40)
A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2* (1999) (39)
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose (2012) (39)
Regulation of the acetylcholine receptor epsilon subunit gene by recombinant ARIA: an in vitro model for transynaptic gene regulation. (1995) (38)
The biology of human epidermal growth factor receptor 2 (1999) (38)
Development of herceptin. (2000) (31)
Selenoprotein A of the clostridial glycine reductase complex: purification and amino acid sequence of the selenocysteine-containing peptide. (1988) (28)
Establishment of Schwann cell lines from normal adult and embryonic rat dorsal root ganglia (1996) (28)
Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models (2003) (27)
Enhanced expression of heregulin in c‐erb B‐2 and c‐Ha‐ras transformed mouse and human mammary epithelial cells (1996) (25)
Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers (2015) (24)
Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay. (1996) (24)
Resolution of sulphydryl oxidase from gamma-glutamyltransferase in bovine milk by covalent chromatography on cysteinylsuccinamidopropyl-glass. (1983) (23)
Inhibition of HER 2 / neu ( erb B-2 ) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER 2-overexpressing , Tamoxifen-resistant Breast Cancer Cells 1 (2000) (21)
Kinetic mechanism and specificity of bovine milk sulphydryl oxidase. (1984) (20)
HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer (2008) (19)
Simultaneous single-step purification of thiolase and NADP-dependent 3-hydroxybutyryl-CoA dehydrogenase from Clostridium kluyveri. (1984) (18)
Structural requirements for ErbB2 transactivation. (2001) (18)
Backbone dynamics of the EGF-like domain of heregulin-alpha. (1998) (18)
Nonidentity of sulfhydryl oxidase and γ-glutamyltransferase in bovine milk (1981) (17)
Purification and immunological studies of selenoprotein A of the clostridial glycine reductase complex. (1987) (16)
Cells HER 2-overexpressing , Tamoxifen-resistant Breast Cancer Kinases Enhances Tamoxifen Action against B-2 ) and Mitogen-activated Protein erb ( neu Inhibition of HER 2 / Updated (2000) (16)
Serological evaluation of Escherichia coli-expressed human T-cell leukemia virus type I env, gag p24, and tax proteins (1990) (15)
Toward an Effective Targeted Chemotherapy for Multiple Myeloma (2009) (15)
Abstract A135: T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner. (2011) (15)
Labeling of cysteine-containing peptides with 2-nitro-5-thiobenzoic acid. (1985) (9)
Selenium-dependent glycine reductase: differences in physicochemical properties and biological activities of selenoprotein A components isolated from Clostridium sticklandii and Clostridium purinolyticum. (1988) (8)
515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel (2008) (8)
Abstract 637: MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors (2011) (7)
Effects of in vivo heregulin beta1 treatment in wild-type and ErbB gene-targeted mice depend on receptor levels and pregnancy. (2001) (7)
Abstract 5607: Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab (2010) (7)
Characterization of selenomethionine in proteins. (1984) (6)
HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment (2016) (6)
AN IMPROVED METHOD FOR QUANTITATION OF SULFHYDRYL CONCENTRATION IN TURBID SAMPLES (1980) (5)
Pari passu dimers of dimers (2012) (5)
Abstract 1207: Preclinical development of 2nd generation HER2-directed antibody-drug conjugates (2016) (4)
Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics. (2007) (4)
Assay of enzyme-catalyzed oxygen-dependent disulfide bond formation. (1987) (3)
Selenomethionine-containing thiolase and 3-hydroxybutyryl-CoA dehydrogenase from Clostridium kluyveri. (1985) (2)
Differential expression of microRNAs induced by trastuzumab emtansine (T-DM1) during megakaryocytopoiesis. (2013) (2)
5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results (2009) (2)
ErbB2/Her2 ectodomain shedding is regulated by a membrane-associated metalloprotease (2005) (2)
TYROSINE PHOSPHATE AND TYROSINE SULFATE IN PROTEINS (1983) (2)
Downregulation of HER3: A potential surrogate for activation of HER2 through heterodimerization may predict clinical benefit in ovarian cancer from pertuzumab, a HER dimerization inhibiting antibody (2007) (2)
Identification of head and neck cancers (SCCHN) that may respond to dual inhibition of EGFR and HER3 signaling. (2012) (2)
Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1 (1999) (2)
Abstract 2721: MEHD7945A, dual specific antibody against EGFR and HER3, augments radiation response in head and neck squamous cell carcinoma (2012) (2)
An open-and-shut case (2003) (2)
Abstract 1212: The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo (2012) (1)
Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells. (2006) (1)
Treatment of HER 2-Amplified Breast Cancer Efficacy of Afucosylated Trastuzumab in the In vivo (2010) (1)
Nonidentity of sulfhydryl oxidase and gama-glutamyltransferase in bovine milk. (1981) (1)
HER2 Overexpression Induces Membrane Deformation that Increases Cell Motility (2014) (1)
Evolution of the MDA-MB-175 breast cancer cell line from a low to a high HER2 expressing tumor line (2005) (1)
ThioMabs: improving safety abd retaining efficacy of antibody drug conjugates (2007) (1)
Panel Discussion II (1987) (0)
208 POSTER Pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of PRO132365, a HER2 antibody-drug conjugte (2006) (0)
Resolution ofsulphydryl oxidase fromy-glutamyltransf erase inbovine milk bycovalent chromatography on cysteinylsuccinamidopropyl-glass (1983) (0)
Use of heregulin as epithelzellenwachstumsfaktor (1999) (0)
Treatment of cancer with the recombinant humanized anti-ErbB2 antibody 2C4 (rhuMAb 2C4) (2003) (0)
Method for treating prostate cancer in a human, article of manufacture and the use of an antibody which binds ErbB2 (2000) (0)
Animal Model Effects of in Vivo Heregulin 1 Treatment in Wild- Type and ErbB Gene-Targeted Mice Depend on Receptor Levels and Pregnancy (2001) (0)
An enzymatic approach to flavor modification. (1980) (0)
Engineering novel ThioFab/Mabs for site specific conjugation of cytotoxic drugs (2006) (0)
5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer (2007) (0)
of Multivalent Antibodies Design, Construction, and In Vitro Analyses (2017) (0)
Use of heterogublina like growth factor epithelial cells. (1999) (0)
Predictive Biomarkers and Personalized Medicine Analysis of Fc g Receptor IIIa and IIa Polymorphisms : Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (0)
Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells 1 (2000) (0)
Epidermal Growth Factor Receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib (2002) (0)
The use of ErbB4 specific antagonists for the treatment of stenosis (2001) (0)
Cytotoxic Drug Conjugate − Trastuzumab-DM 1 , an Antibody Targeting HER 2-Positive Breast Cancer with Updated (2008) (0)
The Nature of Constitutive Activation of HER2 at the Single Molecule Level (2012) (0)
MExpression in Node-negative Breast Cancer : Direct Tissue Quantitation by Computerized Image Analysis and Association of Overexpression with Increased Risk of Recurrent Disease 1 (2006) (0)
Tyrosine Kinase Domain from Epidermal Growth Factor Receptor (2002) (0)
Combined treatment of tumors expressing her (2006) (0)
Use of heregulin as a epitelcellevækstfaktor (1999) (0)
Beyond Cetuximab for Head and Neck Cancer: Dual Target Antibody Blockade of EGFR and HER3 Enhances Radiosensitivity and Overcomes Acquired Resistance to EGFR Inhibitors (2011) (0)
Methods of treatment using conjugates of anti-ErbB-maytansinoid (2000) (0)
Membrane Deformation by HER2 Overexpression Disrupts Epithelial Integrity (2015) (0)
Abstract 3330: HER2 overexpression induces membrane deformation that increases cell motility (2014) (0)
Treatment methods using anti-ErbB-maitansinoid antibody conjugates (2000) (0)
Management of prostate cancer with anti-ErbB2 antibodies. (2000) (0)
Abstract 4396: Conjugation site modulates the stability and biological activity of antibody drug conjugates (2010) (0)
Cancer treatment with the antibody directed against ErbB2 rhuMAb 2C4 (2003) (0)
Combinations of a drug conjugate-anti-HER2 and docetaxel (2009) (0)
Treatment of the cancer with the antibody directed against ErbB2 rhuMAb 2C4. (2003) (0)
246 New platforms of immunoconjugates (2010) (0)
Combinations of an antibody-drug conjugate of anti-HER2 and chemotherapeutic agents, and methods of use (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mark X. Sliwkowski?

Mark X. Sliwkowski is affiliated with the following schools:

Mark X. Sliwkowski's Academic­Influence.com Rankings

Mark X. Sliwkowski's Degrees

Why Is Mark X. Sliwkowski Influential?

Mark X. Sliwkowski's Published Works

Published Works

What Schools Are Affiliated With Mark X. Sliwkowski?

Mark X. Sliwkowski's AcademicInfluence.com Rankings